Optum scientists experienced a successful year in 2019 highlighted by numerous academic achievements. We shared the results of our insightful and collaborative work in several high-impact journals and conference presentations. Our work has largely focused on incorporating and interpreting the voice of the patient in many different therapeutic areas, including amyloidosis, sickle cell disease, ulcerative colitis, mental health and cardiovascular disease. As leaders in patient-reported outcomes (PROs), we also published multiple psychometric and methods papers.

Additionally, we presented results from both our quantitative and qualitative studies in oral, podium and conference presentations. Mixed-methods studies incorporating both quantitative and qualitative work were also accepted by leading conferences.

Following is a complete listing of the publications, presentations and white papers our team presented in 2019.
PUBLICATIONS (ALPHABETICAL BY FIRST AUTHOR)


PRESENTATIONS (CHRONOLOGICAL)

3. Sikora Kessler A, Yarlas A, Lovley A, McCausland KL, Guthrie SD, Pollock M, White MK. Clinical Outcome Assessment Scores for Patients with Transthyretin Amyloidosis with or without Accompanying Cardiomyopathy or Congestive Heart Failure. Poster presented at: American College of Cardiology (ACC) 68th Annual Scientific Session; March 16–18, 2019; New Orleans, LA.
5. Sikora Kessler A, O’Connor S, Guthrie S, Pollock M, McCausland KL. Characterizing Treatment Experience among Patients with Transthyretin Amyloidosis. Poster presented at: Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting; March 25–28, 2019; San Diego, CA.
13. Lovley A, Sikora Kessler A, Guthrie SD, Pollock M, McCausland KL. The Burden of Transthyretin Amyloidosis and Ambulatory Disability on Health-related Quality of Life: Results from an Observational Study. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting; May 18–22, 2019; New Orleans, LA.

15. **Raymond K**, **Lovley A**, **White MK**, Guthrie SD, Pollock M. Health-related Quality of Life in Hereditary Transthyretin Amyloidosis: Qualitative Interviews with Patients. Podium presentation at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting; May 18–22, 2019; New Orleans, LA.


20. **Yarlas A**, Guthrie SD, Pollock M, **Lovley A**, **White MK**. Association between Clinical Outcomes and Quality of Life in Patients with Hereditary Transthyretin Amyloidosis. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting; May 18–22, 2019; New Orleans, LA.


23. **Lovley A**, **Sikora Kessler A**, Guthrie SD, Pollock M, **McCaussland KL**. The burden of transthyretin amyloidosis and ambulatory disability on health-related quality of life: Results from an observational study. Encore poster presented at: 2nd European Meeting for ATTR Amyloidosis for Doctors and Patients 2019; September 2–3, 2019; Berlin, Germany.

24. **Sikora Kessler A**, **Yarlas A**, Pollock M, Guthrie S, **McCaussland KL**. Characterizing the Journey to Diagnosis for Patients with Transthyretin Amyloidosis and Accompanying Congestive Heart Failure. Poster presented at: Heart Failure Society of America Meeting; September 13–16, 2019; Philadelphia, PA.


28. **Sikora Kessler A**, O’Connor S, Pollock M, Guthrie S, **McCaussland K**. Characterizing Treatment Experience among Patients with Transthyretin Amyloidosis. Poster presented at: American Association of Neuromuscular and Electrodiagnostic Medicine 2019 Meeting; October 16–19, 2019; Austin, TX.

29. **Yarlas A**, Guthrie S, Pollock M, **Lovley A**, **White MK**. Association Between Clinical Outcomes and Quality of Life in Patients with Hereditary Transthyretin Amyloidosis. Poster presented at: American Association of Neuromuscular and Electrodiagnostic Medicine 2019 Meeting; October 16–19, 2019; Austin, TX.


31. **Bjorner JB**. Analysis of Minimal Important Change through Item Response Theory Methods. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Meeting; November 2–6, 2019; Copenhagen, Denmark.
32. **Sikora Kessler A**, Pollock M, Guthrie S, **White MK, Raymond K**.
The Impact of Hereditary Transthyretin Amyloidosis on Work-Related Outcomes: A Mixed Methods Approach. Podium presentation at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Meeting, November 2–6, 2019; Copenhagen, Denmark.

33. **McCausland KL**, Haider B, **White MK**, O’Sullivan AK, **Rychlec K**, Akerman S, Saxon A. Clinicians’ Perspectives on Extended-Release Naltrexone to Treat Opioid Use Disorder in Outpatient Settings: Results from an Online Survey. Poster presented at: 43rd Annual Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA) Conference; November 7–9, 2019; Boston, MA


**WHITE PAPERS**


---

To learn more about Optum Patient Insights, please contact us.

Call: 1-800-572-9394
Email: info@qualitymetric.com
Visit: optum.com/patient-insights